Cargando…

Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine

Cariprazine is currently approved for the treatment of patients with schizophrenia (USA and EU), and for manic, depressive, and episodes with mixed features in bipolar I disorder (USA): several randomized controlled studies have also explored its efficacy in patients with major depressive disorder....

Descripción completa

Detalles Bibliográficos
Autores principales:	Batinic, Borjanka, Ristic, Ivan, Zugic, Milica, Baldwin, David S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649660/ https://www.ncbi.nlm.nih.gov/pubmed/34887792 http://dx.doi.org/10.3389/fpsyt.2021.784370

Ejemplares similares

Dopamine in Autism Spectrum Disorders—Focus on D2/D3 Partial Agonists and Their Possible Use in Treatment
por: Mandic-Maravic, Vanja, et al.
Publicado: (2022)

Cariprazine in the Treatment of Bipolar Disorder: Within and Beyond Clinical Trials
por: Do, André, et al.
Publicado: (2021)

Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis
por: Durgam, Suresh, et al.
Publicado: (2017)

Update on schizophrenia and bipolar disorder: focus on cariprazine
por: Roberts, Rona Jeannie, et al.
Publicado: (2016)

Early Clinical Effects of Novel Partial D3/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study)
por: Ivanov, Stanislav V., et al.
Publicado: (2022)

Preferential Effects of Cariprazine on Counteracting the Disruption of Social Interaction and Decrease in Extracellular Dopamine Levels Induced by the Dopamine D(3) Receptor Agonist, PD-128907 in Rats: Implications for the Treatment of Negative and Depressive Symptoms of Psychiatric Disorders
por: Kehr, Jan, et al.
Publicado: (2022)

Partial Agonists and Dual Disorders: Focus on Dual Schizophrenia
por: Peris, Lola, et al.
Publicado: (2021)

Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia
por: Culpepper, Larry, et al.
Publicado: (2022)

Case series: Cariprazine in early-onset schizophrenia
por: Ivanova, Elena, et al.
Publicado: (2023)

New developments in the management of schizophrenia and bipolar disorder: potential use of cariprazine
por: Werner, Felix-Martin, et al.
Publicado: (2015)

Pareidolia in Schizophrenia and Bipolar Disorder
por: Abo Hamza, Eid G., et al.
Publicado: (2021)

Cariprazine, A Dopamine D(2)/D(3) Receptor Partial Agonist, Modulates ABCG2-Mediated Multidrug Resistance in Cancer
por: Hussein, Noor, et al.
Publicado: (2018)

The novel atypical antipsychotic cariprazine demonstrates dopamine D(2) receptor‐dependent partial agonist actions on rat mesencephalic dopamine neuronal activity
por: Delcourte, Sarah, et al.
Publicado: (2018)

Electroencephalographic Microstates in Schizophrenia and Bipolar Disorder
por: Wang, Fanglan, et al.
Publicado: (2021)

Dosing Cariprazine Within and Beyond Clinical Trials: Recommendations for the Treatment of Schizophrenia
por: Rancans, Elmars, et al.
Publicado: (2022)

Cariprazine's Potential in Improving Social Dysfunction in Patients With Schizophrenia: A Perspective
por: Morozov, Petr, et al.
Publicado: (2022)

Clinical effects of Cariprazine and their relationship with polymorphisms of dopamine and serotonin receptors: preliminary results from a prospective study on schizophrenia and bipolar disorder
por: De Pieri, M., et al.
Publicado: (2022)

Imaging Habenula Volume in Schizophrenia and Bipolar Disorder
por: Schafer, Matthew, et al.
Publicado: (2018)

Case Report: Cariprazine in a Patient With Schizophrenia, Substance Abuse, and Cognitive Dysfunction
por: Rodriguez Cruz, Jose, et al.
Publicado: (2021)

Physical Activity Monitoring Preferences in Adults With Bipolar Disorder
por: Janney, Carol A., et al.
Publicado: (2021)

Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?
por: Mohr, Pavel, et al.
Publicado: (2022)

Editorial: Novel antipsychotics within and beyond clinical trials: The treatment of overlapping psychiatric disorders with D3-D2 partial agonists
por: Németh, György, et al.
Publicado: (2022)

Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms
por: Vasiliu, Octavian
Publicado: (2021)

Binding kinetics of cariprazine and aripiprazole at the dopamine D(3) receptor
por: Frank, Annika, et al.
Publicado: (2018)

Molecular Imaging of Dopamine Partial Agonists in Humans: Implications for Clinical Practice
por: Hart, Xenia M., et al.
Publicado: (2022)

Cognitive Impairment in Bipolar Disorder and Schizophrenia: A Systematic Review
por: Vöhringer, Paul A., et al.
Publicado: (2013)

Theory of Mind in Bipolar Disorder, with Comparison to the Impairments Observed in Schizophrenia
por: Mitchell, Rachel L. C., et al.
Publicado: (2016)

Editorial: Genetic Mechanisms of Biomarkers in Schizophrenia, Bipolar Disorder and Depression
por: Tang, Yiguo, et al.
Publicado: (2021)

Case report: Treatment-resistant schizophrenia with auto-aggressive compulsive behavior—Successful management with cariprazine
por: Renemane, Lubova, et al.
Publicado: (2023)

Common and Specific Functional Activity Features in Schizophrenia, Major Depressive Disorder, and Bipolar Disorder
por: Yang, Yongfeng, et al.
Publicado: (2019)

Shared and distinct functional connectivity of hippocampal subregions in schizophrenia, bipolar disorder, and major depressive disorder
por: Song, Yanzhuo, et al.
Publicado: (2022)

Resilience and Cognitive Function in Patients With Schizophrenia and Bipolar Disorder, and Healthy Controls
por: Deng, Mengjie, et al.
Publicado: (2018)

The Therapeutic Potential of Mangosteen Pericarp as an Adjunctive Therapy for Bipolar Disorder and Schizophrenia
por: Ashton, Melanie M., et al.
Publicado: (2019)

Case Report: Long-Acting Oral Cariprazine
por: Dyrmishi, Emanuela, et al.
Publicado: (2022)

The Relationship Between Cognitive Dysfunction and Symptom Dimensions Across Schizophrenia, Bipolar Disorder, and Major Depressive Disorder
por: Zhu, Yue, et al.
Publicado: (2019)

Volumes of hippocampal subfields suggest a continuum between schizophrenia, major depressive disorder and bipolar disorder
por: Cao, Peiyu, et al.
Publicado: (2023)

Cariprazine hydrochloride for schizophrenia
Publicado: (2021)

Exploring the Psychosis Functional Connectome: Aberrant Intrinsic Networks in Schizophrenia and Bipolar Disorder
por: Calhoun, Vince D, et al.
Publicado: (2012)

Gene X Environment Interactions in Schizophrenia and Bipolar Disorder: Evidence from Neuroimaging
por: Geoffroy, Pierre Alexis, et al.
Publicado: (2013)

Risk of Schizophrenia and Bipolar Disorder in Patients With Multiple Sclerosis: Record-Linkage Studies
por: Meier, Ute-Christiane, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ngi1k70h07sf2817ioghb97e0e